Enteric fever, commonly known as typhoid fever, is a severe systemic infection caused by Salmonella Typhi and Paratyphi. Predominantly prevalent in regions with poor sanitation and hygiene, it remains a significant health concern. This article aims to delve into the effective management of enteric fever in clinical practice.
Enteric fever is primarily contracted through the ingestion of contaminated food or water. The clinical presentation can range from mild febrile illness to severe life-threatening complications. Symptoms include high fever, abdominal pain, constipation or diarrhoea, and rose spots on the chest.
Early diagnosis is crucial for effective management. Blood culture remains the gold standard for diagnosis, although it has a sensitivity of only 40-60%. Other diagnostic tests include stool and urine cultures, Widal test, and molecular methods like PCR for rapid detection.
Antibiotic therapy is the cornerstone of management. Empirical therapy with ceftriaxone or azithromycin is recommended until sensitivity results are available. Fluoroquinolones, once first-line treatment, are now reserved for resistant cases due to increasing resistance. Adjunctive therapy includes hydration and electrolyte management.
Vaccination is an effective preventive measure, especially for high-risk populations and travellers. Improvement in sanitation, safe food handling, and safe drinking water are also crucial in controlling enteric fever.
Enteric fever remains a significant public health issue, particularly in regions with inadequate sanitation. Early diagnosis, effective antibiotic therapy, and preventive measures are key to managing this condition. It is also important for healthcare professionals to stay updated on the evolving patterns of antibiotic resistance to ensure effective treatment strategies.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation